Study: Hair Care Regimen May Enhance Minoxidil Response in Women With Hair Loss

Key Takeaways

• A 6-month randomized clinical study found that SEEN’s non-comedogenic hair care regimen combined with minoxidil 5% foam resulted in a 1.7-fold increase in non-vellus hair counts versus minoxidil plus participants’ usual hair products.
• The observer-blinded study enrolled 46 women with mild-to-moderate hair loss and evaluated outcomes using phototrichograms at baseline, 3 months, and 6 months.
• Investigators hypothesize that reducing follicular occlusion and scalp irritation may enhance topical minoxidil penetration and treatment outcomes.

SEEN Hair Care presented new clinical findings at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE), suggesting that a non-comedogenic, non-irritating hair care regimen may improve outcomes with topical minoxidil 5% foam in women with hair loss.

The E-poster reported results from a 6-month, randomized, observer-blinded study involving 46 women aged 25 to 70 years with mild-to-moderate hair loss. Participants in the combination arm used SEEN Shampoo and Conditioner alongside minoxidil 5% foam, while the control group used minoxidil with their usual hair products.

According to the company, women using the SEEN regimen achieved a 70% greater increase in non-vellus hair counts at 6 months compared with controls. Investigators used phototrichograms to assess hair counts at baseline, 3 months, and 6 months.

Patient-reported outcomes also favored the SEEN combination arm, with 92% of participants reporting fuller-looking hair, 88% reporting healthier-looking hair, and 83% reporting thicker-feeling hair at 6 months. Additionally, 79% reported reduced scalp visibility.

In a press release, lead author Iris K. Rubin, MD, founder and chief medical officer of SEEN, said the findings support the concept of maintaining “clear follicles” to optimize topical treatment penetration. The company hypothesizes that traditional hair care products with comedogenic ingredients may impede delivery of topical therapies to the follicle. Topical minoxidil remains the only FDA-approved topical treatment for female pattern hair loss. The study findings have not yet been published in a peer-reviewed journal.

Suggested Titles

1. SEEN Presents Data Linking Hair Care Regimen to Enhanced Minoxidil Efficacy
2. SCALE 2026: SEEN Study Reports Higher Hair Counts With Combination Regimen
3. Non-Comedogenic Hair Care May Improve Minoxidil Outcomes in Women
4. SEEN Clinical Study Explores Role of “Clear Follicles” in Hair Regrowth
5. Observer-Blinded Study Evaluates Hair Care’s Impact on Minoxidil Response